Breye Therapeutics
- Health & Biotech
- Hørsholm, DK
- Private
- breye.com
Danish ophthalmology drug developer advancing orally administered danegaptide and P2X7 antagonist candidates.
$76.7MEquity raised in 2025–20262025 — · 2026 $76.7M · 1 equity round
$76.7MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 1 source
Earlier rounds not yet sourced. Breye Therapeutics raised before 29 Sep 2026; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series AAmount$76.7MEUR 67.5MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 9
- Mission BioCapital1
- Novo Holdings1
- Catalyze Capital
- EIFO
- Innovestor Life Science
- Ljungström
- Modi Ventures
- Pappas Capital
- Sound Bioventures
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
AnaCardioHealth · $90M in 2025–2026Shared: Novo Holdings, Sound Bioventures +2OMass TherapeuticsHealth · $310M in 2025–2026Shared: Novo HoldingsSubraDeep Tech · $58M in 2025–2026Shared: Novo HoldingsMapLight TherapeuticsHealth · $373M in 2025–2026Shared: Novo HoldingsDren BioHealth · $350M in 2025–2026Shared: Mission BioCapitalEuclydAI Infra · $230M in 2025–2026Shared: EIFO
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Breye Therapeutics and its logo are trademarks of their owners, used here for identification only.
